CoChat

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis

The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.

Abstract

BACKGROUND: No randomized, controlled trial of screening for diabetes has been conducted. In the absence of direct evidence, cost-effectiveness models may provide guidance about preferred screening strategies. OBJECTIVE: To estimate the incremental cost-effectiveness of 2 diabetes screening strategies: screening targeted to people with hypertension and universal screening. DESIGN: Markov model. DATA SOURCES: United Kingdom Prospective Diabetes Study, Hypertension Optimal Treatment trial, and recent cost data. TARGET POPULATION: General primary care population in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Health care system. INTERVENTIONS: Diabetes screening targeted to people with hypertension and universal screening. OUTCOME MEASURES: Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 U.S. dollars) and QALYs discounted at a 3% annual rate. RESULTS OF BASE-CASE ANALYSIS: At all ages, incremental cost-effectiveness ratios were more favorable for screening targeted to people with hypertension than for universal screening. For example, at age 55 years, the cost per QALY for targeted screening compared with no screening was 34,375 dollars, whereas the cost per QALY for universal screening compared with targeted screening was 360,966 dollars. Screening was more cost-effective for ages 55 to 75 years than for younger ages. RESULTS OF SENSITIVITY ANALYSIS: In single-way and probabilistic sensitivity analyses, findings were robust to therapy costs, screening costs, screening lead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk reduction for stroke attributable to intensive hypertension control. LIMITATIONS: We did not consider screening targeted to persons with dyslipidemia, and we used studies of people whose diabetes was detected clinically to estimate screening benefits. CONCLUSIONS: Diabetes screening targeted to people with hypertension is more cost-effective than universal screening. The most cost-effective strategy is targeted screening at age 55 to 75 years.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-140-9-200405040-00008

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 4

  1. Marshall KG, 1999, CMAJ, 160, 1592
  2. American Diabetes Association., 2001, Diabetes Care, 24, S21
  3. Estacio RO, 2000, Diabetes Care, 23, B54
  4. 10.1001/archinte.1992.00400150120022 · doi:10.1001/archinte.1992.00400150120022 · Paper page

Cited by

See all 178

Metadata

Authors
Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Annals of Internal Medicine
Published
2004-05-04
Volume
140
Issue
9
Pages
689-699
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2007583174
Cited by
178
References
51
Citations by year
2025: 2 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 11 · 2013: 8 · 2012: 11
FWCI
22.90
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (290-97-0011, 200-97-0621)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, diabetes screening, cost-effectiveness, targeted screening, universal screening, hypertension, quality-adjusted life years, primary care, Markov model, stroke risk reduction
MeSH terms
Adult, Aged, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Hypertension, Male, Markov Chains, Mass Screening, Middle Aged, Sensitivity and Specificity, Disease Progression, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-140-9-200405040-00008
The paper
Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M. (2004). Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-140-9-200405040-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.